TABLE 5
FROM:
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma
M E Burge, D Smith, C Topham, D P Jackson, D A Anthoney, F Halstead and M T Seymour
BACK TO ARTICLETable 5. Worst toxicity experienced (n=30)
| Worst toxicity grade | Number of patients (%) |
|---|---|
| 0 | 4 (13) |
| 1 | 1 (3) |
| 2 | 13 (43) |
| 3 | 12 (40) |
| 4 | 1 (3) |